Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Core Points - Lexaria Bioscience Corp. has entered into a definitive agreement to sell 2,666,667 shares of common stock at a price of $1.50 per share in a registered direct offering [1] - Concurrently, the company will issue unregistered warrants to purchase an additional 2,666,667 shares at an exercise price of $1.37 per share, which will be immediately exercisable and expire in five years [1] - The total gross proceeds from the offering are expected to be approximately $4.0 million before deducting fees and expenses [2] Offering Details - The shares are being offered under a "shelf" registration statement that was declared effective by the SEC on January 30, 2025 [3] - The offering is made only by means of a prospectus, which will be filed with the SEC and available on their website [3] - The warrants are issued in a private placement and have not been registered under the Securities Act, limiting their sale in the U.S. [4] Company Overview - Lexaria's DehydraTECH™ technology enhances drug delivery through oral administration, improving bio-absorption and reducing side effects [6] - The company holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide [6]